Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

ABSTRACT: Multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg mesalamine, 1200mg mesalamine or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients for 2 years.

DISEASE(S): Lynch Syndrome,Colorectal Cancer Prevention In Lynch Syndrome,Colorectal Cancer,Colorectal Neoplasms,Colorectal Neoplasms, Hereditary Nonpolyposis

PROVIDER: 2238040 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR